Erelzi is manufactured by Sandoz Inc., based in Princeton, New Jersey, at Novartis Pharma in Stein, Switzerland.
US Food and Drug Administration approved a new bio-similar drug Erelzi that contains active ingredient etanercept-szzs for the treatment of multiple inflammatory disease. Multiple Inflammatory disease includes rheumatoid arthritis (RA) which is swelling of joints and periphery tissues along with inflammation, systemic lupus erythematosus (SLE) which causes inflammation and swelling of skin, joints, kidneys, brain, and other organs and metabolic system disease like celiac sprue disease in which intestine produces inflammatory response upon gluten (barley, rye and wheat) intake that causes damage to the lining of the small intestine.
Erelzi can be used in combination with DMARD's ( disease modifying anti-rheumatic drugs) like methotrexate for the treatment of psoriatic arthritis, ankylosing spondylitis, plaque psoriasis and other auto-immune disorders. Erelzi should be used with caution because it may increase the risk of infections like T.B (tuberculosis), histoplasmosis, live and kidney disease. Erelzi should be used only in case where no appropriate alternative is available because etanercept containing products may increase the risk of malignancy upon prolong intake. Erelzi should not be administered to patients with sepsis.
US Food and Drug Administration approved a new bio-similar drug Erelzi that contains active ingredient etanercept-szzs for the treatment of multiple inflammatory disease. Multiple Inflammatory disease includes rheumatoid arthritis (RA) which is swelling of joints and periphery tissues along with inflammation, systemic lupus erythematosus (SLE) which causes inflammation and swelling of skin, joints, kidneys, brain, and other organs and metabolic system disease like celiac sprue disease in which intestine produces inflammatory response upon gluten (barley, rye and wheat) intake that causes damage to the lining of the small intestine.
Erelzi can be used in combination with DMARD's ( disease modifying anti-rheumatic drugs) like methotrexate for the treatment of psoriatic arthritis, ankylosing spondylitis, plaque psoriasis and other auto-immune disorders. Erelzi should be used with caution because it may increase the risk of infections like T.B (tuberculosis), histoplasmosis, live and kidney disease. Erelzi should be used only in case where no appropriate alternative is available because etanercept containing products may increase the risk of malignancy upon prolong intake. Erelzi should not be administered to patients with sepsis.
Erelzi Cost, Side effects, Uses, Dosage for Multiple Inflammatory Diseases
 Erelzi Side effects
During clinical trials Erelzi shows some side effects that were moderate to severe. There side effects are
U.S FDA approved Erelzi for severe kind of multiple inflammatory disease like rheumatoid arthritis, Plaque arthritis, idiopathic juvenile arthritis, ankylosing spondylitis and other auto-immune diseases in combination with some other suitable agents like DMARD's.
Moderate Side effects
- Rashes
- Nausea
- Vomiting
- Dyspepsia
- Abdominal pain
- Fatigue
Severe Side effects
- Increased risk of malignancy
- Increased risk of tuberculosis
- Increased risk of fungal infection (histoplasmosis)
- Increased risk of sepsis.Â
Erelzi Prescribing information or Uses
U.S FDA approved Erelzi for severe kind of multiple inflammatory disease like rheumatoid arthritis, Plaque arthritis, idiopathic juvenile arthritis, ankylosing spondylitis and other auto-immune diseases in combination with some other suitable agents like DMARD's.
0 Comments
For comments please reply here.......